Pharmaceutical companies should this week learn whether they will be expected to reveal confidential pricing arrangements agreed in other countries when seeking reimbursement for new drugs in Italy. The Italian medicines agency and pricing and reimbursement body, AIFA, is due to consult on a draft decree that sets out guidelines on how changes to the pricing and reimbursement system will work in practice.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?